Mina Zion is the associate director for innovation and commercialization for the Weill Cornell Medicine campus in Doha, Qatar (WCM-Q). In this capacity, he oversees the broadening of the research enterprise in Doha by leading external research alliances with global partners across North America, Middle East and North Africa and the EU.
Prior to joining Weill Cornell Medicine – Qatar, he was the corporate relations officer and interim president of Sentrimed Corporation, a university founded clinical stage biotech company that develops therapeutic drug candidates for targeting oral squamous cell carcinoma. In this role, he was responsible for identifying and negotiating a portfolio of licensing, partnership and manufacturing agreements, in addition to leading corporate fundraising and overseeing multiple c-suite and board appointments. Mr. Zion assumed similar roles at the University of Pennsylvania, at the University of Southern California and was the founding executive director of the Rowan University Office of Technology Commercialization, where he successfully led an effort to attract leading biotech partners to the region to engage in sponsored research, startup and licensing opportunities. Earlier in his career, Mr. Zion was an innovation scout at BASF Venture Capital and a Thomas G. Labrecque Scholar at JPMorgan Chase.
Mr. Zion received his Juris Doctorate from Rutgers University School of Law where he studied pharmaceutical, administrative and patent law. He holds a B.S. in Chemical and Biological Engineering from New York University Polytechnic Institute.
